Pliant Therapeutics, Inc.

PLRX

US7291391057

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of Î±vÃ6 and Î±vÃ1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of Î±vÃ1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of Î±vÃ8 and Î±vÃ1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Sector

Pharmaceuticals

Calendar

02:30am - European Association for the Study of the Liver Congress - Abstract No: LB27

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pliant Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.14 USD

Average target price

41.08 USD

Spread / Average Target

+238.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PLIANT THERAPEUTICS, INC.	-32.99%	727M
ELI LILLY AND COMPANY	+42.83%	748B
NOVO NORDISK A/S	+34.11%	598B
JOHNSON & JOHNSON	-5.70%	356B
MERCK & CO., INC.	+18.06%	325B
ABBVIE INC.	+4.63%	283B
ASTRAZENECA PLC	+17.02%	245B
NOVARTIS AG	+9.26%	211B
ROCHE HOLDING AG	-4.21%	209B
PFIZER, INC.	+2.43%	166B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 03:59:44 2024-06-04 pm EDT			5-day change	1st Jan Change
12.14 ^USD	+0.71%		-5.78%	-32.99%

May. 14	Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	MT
May. 14	Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial	MT

Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	May. 14	MT
Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial	May. 14	MT
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis	May. 14	CI
Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating	May. 07	MT
RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk	May. 07	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	Mar. 12	CI
RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	Mar. 05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	Feb. 28	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	Feb. 06	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	Feb. 05
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	Feb. 05	MT
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	Feb. 05	MT
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	Feb. 04	CI
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	Jan. 19	MT
Top Premarket Decliners	Jan. 11	MT
Transcript : Pliant Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	Jan. 09
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	Nov. 10	MT
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Pliant Therapeutics Appoints Chief Regulatory Officer	23-10-16	MT
Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer	23-10-16	CI
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	23-09-27	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	23-09-26
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	23-09-26	CI